Kwangdong Pharmaceutical

009290 · KOSPI · ₩009290 · 광동제약

₩6,360▼ ₩90 (1.40%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩8,537

vs the current price (₩6,360)

Enterprise value
₩481B
Equity value
₩425B
WACC
6.5%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
—
Base
₩8,537
+34.2%
Bull
₩31,354
+393.0%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (2.3%).

Revenue growth

  • 5%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (5% a year, annual reports), fading to 3% by year 5.

  • 4.5%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (5% a year, annual reports), fading to 3% by year 5.

  • 4%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (5% a year, annual reports), fading to 3% by year 5.

  • 3.5%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (5% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (5% a year, annual reports), fading to 3% by year 5.

Business

  • 2.3%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 2.3%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 2.9%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 10.4%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.11%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-28.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.18, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.61%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩1.7T
Net debt (borrowings and leases − cash and deposits)
₩126B
+ Stakes and investments
₩137B
Associates, long-term financial assets and deposits (book value)
− Minority interests
₩66B
Shares
49,799,808
Share price
₩6,360
Market cap
₩317B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩1.5T₩1.6T₩1.7T₩1.8T₩1.9T₩1.9T₩2T₩2.1T
Growth5.8%8.3%1.1%5.0%4.5%4.0%3.5%3.0%
EBIT₩42B₩30B₩31B₩41B₩43B₩45B₩46B₩48B
EBIT margin2.8%1.8%1.9%2.3%2.3%2.3%2.3%2.3%
After-tax EBIT₩31B₩22B₩23B₩30B₩31B₩32B₩34B₩35B
+ Depreciation———₩41B₩43B₩45B₩46B₩48B
− Capital spending₩35B₩78B₩26B₩52B₩54B₩56B₩58B₩60B
− Working capital−₩171B₩304B−₩104B₩8.9B₩8.4B₩7.8B₩7.1B₩6.3B
Free cash flow———₩10B₩12B₩13B₩14B₩16B
Discount factor———0.9390.8820.8290.7790.731
Present value———₩9.6B₩10B₩11B₩11B₩12B

Terminal value ₩585B, worth ₩428B today: 89% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩12,825 a share)Now 0.50×₩6,1300.48×₩7,4490.58×₩8,8990.69×
Price / earnings (last 12 months: ₩438 a share)Now 14.5×₩3,5688.14×₩4,64510.6×₩6,42014.7×
P/E on run-rate earnings (Q2 2026 × 4: ₩218 a share)Now 29.2×₩1,7718.14×₩2,30510.6×₩3,18714.7×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
5.5%₩9,650₩10,498₩11,588₩13,041₩15,078
6.0%₩8,455₩9,084₩9,868₩10,875₩12,216
6.5%₩7,482₩7,958₩8,537₩9,259₩10,184
7.0%₩6,675₩7,041₩7,477₩8,008₩8,669
7.5%₩5,995₩6,279₩6,613₩7,011₩7,495

Now (TTM)

Market cap
₩317B
Enterprise value
₩443B
P/E
14.5×
P/B
0.5×
P/S
0.2×
EV/EBITDA
—
Dividend yield
1.6%

Over time (at each year end)

20252024202320222021
Price₩5,860₩5,440₩7,430₩5,960₩7,430
Market cap₩292B₩271B₩370B₩297B₩370B
P/E13.9×6.7×10.0×12.3×15.4×
P/B0.4×0.5×0.7×0.6×0.7×
P/S0.2×0.2×0.2×0.2×0.3×
EV/EBITDA—————
Dividend yield1.7%1.8%———

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Kwangdong Pharmaceutical14.5×0.5×0.2×—1.6%
Samsung Biologics32.1×7.6×14.0×—0.0%
Celltrion27.8×2.4×8.9×—0.0%
Alteogen78.8×28.4×59.9×—0.1%
Yuhan24.8×2.5×2.6×32.5×0.8%
SK biopharmaceuticals14.6×5.7×6.8×—0.0%
HLB—15.4×54.6×—0.0%
Similar companies (median)27.8×6.7×11.5×32.5×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Kwangdong Pharmaceutical / 광동제약 / 009290 / KRX:009290

Source: KRX statistical information